دورية أكاديمية
The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
| العنوان: | The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease. |
|---|---|
| المؤلفون: | Kumar S; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Leigh ND; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Cao X; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.; Department of Microbiology and Immunology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2018 Dec 21; Vol. 9, pp. 3003. Date of Electronic Publication: 2018 Dec 21 (Print Publication: 2018). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Costimulatory and Inhibitory T-Cell Receptors/*metabolism , Graft vs Host Disease/*immunology , Hematopoietic Stem Cell Transplantation/*adverse effects , Signal Transduction/*immunology , T-Lymphocytes/*immunology, Clinical Trials as Topic ; Costimulatory and Inhibitory T-Cell Receptors/agonists ; Costimulatory and Inhibitory T-Cell Receptors/antagonists & inhibitors ; Costimulatory and Inhibitory T-Cell Receptors/immunology ; Graft vs Host Disease/therapy ; Graft vs Leukemia Effect/drug effects ; Graft vs Leukemia Effect/immunology ; Humans ; Immunologic Factors/pharmacology ; Immunologic Factors/therapeutic use ; Immunotherapy/methods ; Major Histocompatibility Complex/immunology ; Signal Transduction/drug effects ; T-Lymphocytes/drug effects ; T-Lymphocytes/metabolism ; Transplantation, Homologous/adverse effects ; Treatment Outcome |
| مستخلص: | Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective immunotherapeutic approach for various hematologic and immunologic ailments. Despite the beneficial impact of allo-HCT, its adverse effects cause severe health concerns. After transplantation, recognition of host cells as foreign entities by donor T cells induces graft-vs.-host disease (GVHD). Activation, proliferation and trafficking of donor T cells to target organs and tissues are critical steps in the pathogenesis of GVHD. T cell activation is a synergistic process of T cell receptor (TCR) recognition of major histocompatibility complex (MHC)-anchored antigen and co-stimulatory/co-inhibitory signaling in the presence of cytokines. Most of the currently used therapeutic regimens for GVHD are based on inhibiting the allogeneic T cell response or T-cell depletion (TCD). However, the immunosuppressive drugs and TCD hamper the therapeutic potential of allo-HCT, resulting in attenuated graft-vs.-leukemia (GVL) effect as well as increased vulnerability to infection. In view of the drawback of overbroad immunosuppression, co-stimulatory, and co-inhibitory molecules are plausible targets for selective modulation of T cell activation and function that can improve the effectiveness of allo-HCT. Therefore, this review collates existing knowledge of T cell co-stimulation and co-inhibition with current research that may have the potential to provide novel approaches to cure GVHD without sacrificing the beneficial effects of allo-HCT. |
| References: | Ann Oncol. 2004 Apr;15(4):653-60. (PMID: 15033675) Mol Cell Biol. 2005 Nov;25(21):9543-53. (PMID: 16227604) Blood. 2000 Apr 1;95(7):2434-9. (PMID: 10733518) Biol Blood Marrow Transplant. 2008 May;14(5):518-30. (PMID: 18410894) J Clin Invest. 1997 Aug 15;100(4):904-11. (PMID: 9259590) Pediatr Blood Cancer. 2015 Dec;62(12):2216-22. (PMID: 26291959) J Immunol. 2017 Jul 1;199(1):336-347. (PMID: 28550198) Blood. 1998 Oct 15;92(8):2963-70. (PMID: 9763584) J Immunol. 2006 Jun 15;176(12):7394-401. (PMID: 16751384) Blood. 1996 Feb 15;87(4):1232-7. (PMID: 8608209) Br J Pharmacol. 2010 Oct;161(3):512-26. (PMID: 20880392) Leukemia. 2015 Oct;29(10):2062-8. (PMID: 26228813) N Engl J Med. 2006 Sep 7;355(10):1018-28. (PMID: 16908486) J Immunol. 2005 Mar 1;174(5):3051-8. (PMID: 15728519) Bone Marrow Transplant. 1991 Jul;8(1):51-8. (PMID: 1833016) Front Immunol. 2015 Jan 15;5:679. (PMID: 25642230) J Immunol. 2011 Mar 1;186(5):2739-49. (PMID: 21263067) J Immunol. 2013 Jul 1;191(1):200-7. (PMID: 23729441) Ann Hematol. 2015 Sep;94(9):1505-14. (PMID: 26051902) J Immunol. 1994 Sep 15;153(6):2562-7. (PMID: 8077666) Am J Hematol. 2015 Nov;90(11):998-1007. (PMID: 26223969) Immunol Cell Biol. 1999 Feb;77(1):1-10. (PMID: 10101680) Curr Opin Immunol. 2000 Jun;12(3):256-66. (PMID: 10781404) J Biol Chem. 1996 Jan 19;271(3):1591-8. (PMID: 8576157) Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S58-64. (PMID: 18545246) Expert Rev Hematol. 2010 Jun;3(3):285-99. (PMID: 20871781) Int J Hematol. 2007 Jul;86(1):84-90. (PMID: 17675273) Nat Rev Immunol. 2013 Apr;13(4):227-42. (PMID: 23470321) Sci Transl Med. 2015 Nov 25;7(315):315ra191. (PMID: 26606970) Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30. (PMID: 23791624) J Hematother Stem Cell Res. 2000 Jun;9(3):367-74. (PMID: 10894358) Immunity. 2001 Dec;15(6):935-45. (PMID: 11754815) Clin Exp Immunol. 2006 Jul;145(1):36-43. (PMID: 16792671) Biol Blood Marrow Transplant. 2017 May;23(5):820-829. (PMID: 28192251) J Immunol. 2006 Mar 1;176(5):2790-8. (PMID: 16493035) J Neuroimmunol. 2006 Feb;171(1-2):145-55. (PMID: 16300832) Mol Med Rep. 2012 Apr;5(4):910-6. (PMID: 22246571) J Immunol. 2015 Jun 1;194(11):5294-304. (PMID: 25917101) Ann Hematol. 2015 Nov;94(11):1907-19. (PMID: 26264693) Eur J Haematol. 2016 Sep;97(3):232-8. (PMID: 26613546) Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15. (PMID: 18648374) Annu Rev Immunol. 2009;27:591-619. (PMID: 19132916) Immunol Lett. 2013 Jan;149(1-2):101-9. (PMID: 23254121) Blood. 2001 Oct 1;98(7):2043-51. (PMID: 11567988) Blood. 1994 Jun 15;83(12):3815-25. (PMID: 7515723) Immunity. 2007 Mar;26(3):299-310. (PMID: 17363299) Bone Marrow Transplant. 2001 Jul;28(2):121-9. (PMID: 11509929) Transplantation. 2008 Oct 27;86(8):1125-34. (PMID: 18946352) Transplant Proc. 2005 Jan-Feb;37(1):57-61. (PMID: 15808546) Biol Blood Marrow Transplant. 2011 Jul;17(7):962-9. (PMID: 21447398) Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a002469. (PMID: 20300214) J Immunol. 1997 Jan 1;158(1):29-39. (PMID: 8977172) Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):87-97. (PMID: 17222778) Nat Rev Immunol. 2002 Feb;2(2):116-26. (PMID: 11910893) Clin Immunol. 2015 Dec;161(2):278-83. (PMID: 26327693) J Immunol. 2017 Nov 15;199(10):3700-3710. (PMID: 29046346) J Immunol. 2000 May 1;164(9):4564-8. (PMID: 10779758) Blood. 2013 Mar 14;121(11):1951-60. (PMID: 23293083) Int J Cancer. 2016 Mar 1;138(5):1256-68. (PMID: 26376181) J Exp Med. 2016 Jan 11;213(1):123-38. (PMID: 26694968) Blood. 2015 Dec 24;126(26):2781-9. (PMID: 26508783) Stem Cells Dev. 2010 Jan;19(1):27-38. (PMID: 19788399) Immunol Today. 1993 Apr;14(4):177-83. (PMID: 8499078) Immunology. 2002 Apr;105(4):369-74. (PMID: 11985657) Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6346-51. (PMID: 9177220) Front Immunol. 2018 Apr 24;9:669. (PMID: 29740427) Blood. 2010 May 27;115(21):4293-301. (PMID: 20233969) J Immunol. 2006 Oct 1;177(7):4281-7. (PMID: 16982862) J Immunol. 2007 Feb 1;178(3):1293-300. (PMID: 17237375) Eur J Immunol. 1999 Oct;29(10):3160-7. (PMID: 10540327) Int Immunopharmacol. 2015 Dec;29(2):383-392. (PMID: 26507167) Blood. 2012 Jul 19;120(3):682-90. (PMID: 22677125) Mol Cell Biol. 2000 Feb;20(4):1426-35. (PMID: 10648627) Bone Marrow Transplant. 1990 Apr;5(4):269-72. (PMID: 2337738) J Hepatol. 2003 Oct;39(4):587-94. (PMID: 12971970) J Immunol. 2007 Aug 1;179(3):1669-80. (PMID: 17641033) Br J Haematol. 2004 Sep;126(5):697-703. (PMID: 15327522) Semin Immunol. 2009 Oct;21(5):265-72. (PMID: 19524453) Cell Mol Immunol. 2010 Jan;7(1):44-50. (PMID: 20081875) Transplant Proc. 2007 Dec;39(10):3391-5. (PMID: 18089391) J Exp Med. 1997 Jul 7;186(1):47-55. (PMID: 9206996) J Leukoc Biol. 2000 May;67(5):725-34. (PMID: 10811014) Int Immunol. 2004 Apr;16(4):533-8. (PMID: 15039383) Pediatr Transplant. 2010 Jun;14(4):540-8. (PMID: 20136724) Blood. 2009 Nov 12;114(20):4575-82. (PMID: 19721011) F1000Res. 2017 May 3;6:617. (PMID: 28529723) Diabetes. 2008 Jul;57(7):1878-86. (PMID: 18420485) J Immunol. 2008 Nov 15;181(10):7380-9. (PMID: 18981161) Nat Med. 1997 Jun;3(6):682-5. (PMID: 9176498) J Exp Med. 2012 May 7;209(5):903-11. (PMID: 22547653) Mol Immunol. 1996 Jan;33(1):63-70. (PMID: 8604225) J Exp Med. 2004 Jul 19;200(2):149-57. (PMID: 15249593) Nat Immunol. 2014 May;15(5):406-8. (PMID: 24747702) Blood. 2009 Oct 1;114(14):3101-12. (PMID: 19602708) PLoS One. 2014 Jan 27;9(1):e86551. (PMID: 24475140) Blood. 2013 Sep 12;122(11):1863-72. (PMID: 23878143) Blood. 2013 Apr 25;121(17):3511-20. (PMID: 23430112) Nat Med. 2013 Dec;19(12):1632-7. (PMID: 24270545) J Immunol. 1998 May 1;160(9):4225-31. (PMID: 9574523) Blood. 2009 Sep 10;114(11):2323-32. (PMID: 19617579) ScientificWorldJournal. 2011;11:1908-31. (PMID: 22125447) Curr Opin Immunol. 2012 Apr;24(2):246-51. (PMID: 22285893) Blood. 2003 May 1;101(9):3741-8. (PMID: 12521997) Tissue Antigens. 2004 Sep;64(3):215-25. (PMID: 15304001) J Immunol. 2007 Feb 1;178(3):1542-52. (PMID: 17237403) Bone Marrow Transplant. 2003 Feb;31(4):229-39. (PMID: 12621457) Cell Signal. 2001 Jun;13(6):389-400. (PMID: 11384837) Mol Med Rep. 2016 Feb;13(2):1395-403. (PMID: 26647759) Blood. 2015 Jan 29;125(5):784-92. (PMID: 25452614) Blood. 2009 Apr 16;113(16):3865-74. (PMID: 19168788) Transplantation. 1994 Sep 15;58(5):602-10. (PMID: 8091487) Nat Immunol. 2014 May;15(5):431-8. (PMID: 24658051) Biol Res. 2012;45(3):307-16. (PMID: 23283440) Blood. 2005 Apr 1;105(7):2845-51. (PMID: 15591118) Nat Immunol. 2000 Nov;1(5):433-40. (PMID: 11062504) Chem Biol Interact. 2009 Aug 14;180(3):460-4. (PMID: 19416722) Blood. 1995 May 1;85(9):2607-18. (PMID: 7537122) Trends Immunol. 2002 Jun;23(6):285-90. (PMID: 12072366) Am J Hematol. 2015 Feb;90(2):144-8. (PMID: 25353395) Ann Hematol. 2016 Jan;95(2):311-23. (PMID: 26611853) J Immunol. 1997 Oct 1;159(7):3460-73. (PMID: 9317145) FEBS Lett. 2004 Sep 10;574(1-3):37-41. (PMID: 15358536) J Clin Invest. 1998 Aug 1;102(3):473-82. (PMID: 9691083) |
| معلومات مُعتمدة: | R01 HL135325 United States HL NHLBI NIH HHS |
| فهرسة مساهمة: | Keywords: T cells; allogeneic hematopoietic cell transplantation (allo-HCT); co-stimulation/co-inhibition; graft -vs.-leukemia (GVL) effect; graft-vs.-host disease (GVHD) |
| المشرفين على المادة: | 0 (Costimulatory and Inhibitory T-Cell Receptors) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20190111 Date Completed: 20191025 Latest Revision: 20200403 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6309815 |
| DOI: | 10.3389/fimmu.2018.03003 |
| PMID: | 30627129 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2018.03003 |